FASN and non-small cell lung carcinoma: Together, the data suggest that the increased cell growth imparted by EGFR mutant overexpression correlates with the re‐establishment of EGFR‐FASN signaling axis, and this phenomenon is exclusive to Gefitinib‐resistant EGFR mutant NSCLC cells.